

# PRODUCT INFORMATION




## Atogepant

Item No. 35899

**CAS Registry No.:** 1374248-81-3  
**Formal Name:** (3'S)-1',2',5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidiny]-2'-oxo-spiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide

**MF:** C<sub>29</sub>H<sub>23</sub>F<sub>6</sub>N<sub>5</sub>O<sub>3</sub>  
**FW:** 603.5  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Atogepant is supplied as a solid. A stock solution may be made by dissolving the atogepant in the solvent of choice, which should be purged with an inert gas. Atogepant is soluble in methanol and DMSO.

### Description

Atogepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor ( $IC_{50} = 0.026 \text{ nM}$ ).<sup>1</sup> It is selective for the CGRP receptor over the adrenomedullin receptors ( $AM_1$ ) and  $AM_2$ , calcitonin (CT) receptor, amylin receptor 1 ( $AMY_1$ ), and  $AMY_3$  receptor ( $IC_{50}s = >18,000, 400, 6,274, 2.4$  and  $1,418 \text{ nM}$ , respectively). Atogepant (3-30 mg/kg) increases the mechanical pain threshold in the von Frey test in a rat model of nitroglycerin-induced migraine. Formulations containing atogepant have been used in the prevention of episodic migraines.

### Reference

1. Moore, E., Bell, I.M., Fraley, M.E., *et al.* Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist. *Cephalalgia* **44(1)**, 3331024231226186 (2024).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/16/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM